Table 2. Significant pathways of esophageal cancer.
| Pathway ID | Pathway title | Adjusted P-value* | Associated Risk Genes Found | % Associated Risk Genes | Fold enrichment |
|---|---|---|---|---|---|
| GO:0002377 | immunoglobulin production | 6.79E-03 | FOXP1, IL6, XBP1, XRCC4 | 4.44 | 7.83 |
| GO:0002700 | regulation of production of molecular mediator of immune response | 7.54E-03 | FOXP1, IL6, TGFB2, XBP1 | 4.26 | 7.50 |
| GO:0004022 | alcohol dehydrogenase (NAD) activity | 1.50E-10 | ADH1A, ADH1B, ADH1C, ADH4, ADH6, ADH7 | 75.00 | 132.18 |
| GO:0004030 | aldehyde dehydrogenase (NAD(P)+) activity | 1.08E-04 | ADH4, ADH7, ALDH2 | 37.50 | 66.09 |
| GO:0005178 | integrin binding | 3.50E-03 | ADAMTS5, FN1, ITGA6, PPAP2B, PTPN2 | 4.35 | 7.66 |
| GO:0005501 | retinoid binding | 6.21E-03 | ADH4, ADH7, UGT2B7 | 6.82 | 12.02 |
| GO:0006069 | ethanol oxidation | 2.66E-11 | ADH1A, ADH1B, ADH1C, ADH4, ADH6, ADH7, ALDH2 | 63.64 | 112.15 |
| GO:0006493 | protein O-linked glycosylation | 8.74E-03 | ADAMTS5, GALNT13, MUC4, ST6GAL1 | 4.00 | 7.05 |
| GO:0006656 | phosphatidylcholine biosynthetic process | 3.32E-03 | CHEK2, FABP5, SLC44A5 | 9.38 | 16.52 |
| GO:0006805 | xenobiotic metabolic process | 3.34E-04 | ADH1A, ADH1B, ADH1C, ADH4, ADH6, ADH7, ALDH2, SULT1A1 | 4.40 | 7.75 |
| GO:0007431 | salivary gland development | 1.22E-03 | FGFR2, IL6, TGFB2, XBP1 | 8.70 | 15.32 |
| GO:0010883 | regulation of lipid storage | 5.73E-03 | IL6, PTPN2, SREBF2 | 7.14 | 12.59 |
| GO:0030134 | ER to Golgi transport vesicle | 2.11E-04 | HLA-A, HLA-DPA1, HLA-G, KIAA0368, SREBF2 | 9.62 | 16.95 |
| GO:0030176 | integral component of endoplasmic reticulum membrane | 2.05E-04 | CLN3, HLA-A, HLA-DPA1, HLA-G, SREBF2, TBL2, XBP1 | 5.65 | 9.95 |
| GO:0030818 | negative regulation of cAMP biosynthetic process | 4.25E-03 | EDNRA, GNAI2, GRM3 | 8.33 | 14.69 |
| GO:0031016 | pancreas development | 7.75E-03 | GATA6, GNAI2, IL6, XBP1 | 4.17 | 7.34 |
| GO:0031069 | hair follicle morphogenesis | 3.32E-03 | FGFR2, RUNX1, TGFB2 | 9.38 | 16.52 |
| GO:0032729 | positive regulation of interferon-gamma production | 2.19E-03 | HLA-A, HLA-DPA1, IL18R1, PDE4D | 7.02 | 12.37 |
| GO:0033002 | muscle cell proliferation | 3.53E-04 | EDNRA, FGFR2, FOXP1, GATA6, IL6, PDE4D, TGFB2 | 5.07 | 8.94 |
| GO:0034774 | secretory granule lumen | 3.71E-03 | FN1, GNAI2, IL6, TGFB2 | 5.63 | 9.93 |
| GO:0042093 | T-helper cell differentiation | 5.42E-03 | FOXP1, IL18R1, IL6 | 7.50 | 13.22 |
| GO:0042307 | positive regulation of protein import into nucleus | 2.01E-03 | IL18R1, IL6, KANK1, XBP1, ZIC1 | 5.32 | 9.37 |
| GO:0042439 | ethanolamine-containing compound metabolic process | 7.43E-03 | CHEK2, CLN3, FABP5, SLC44A5 | 4.30 | 7.58 |
| GO:0042987 | amyloid precursor protein catabolic process | 1.42E-03 | CLN3, FKBP1A, HAP1 | 14.29 | 25.18 |
| GO:0043368 | positive T cell selection | 2.16E-03 | DOCK2, IL6, PTPN2 | 11.54 | 20.33 |
| GO:0046164 | alcohol catabolic process | 1.17E-02 | ADH4, ADH7, ALDH2 | 5.08 | 8.96 |
| GO:0046631 | alpha-beta T cell activation | 3.06E-03 | DOCK2, FOXP1, HLA-A, IL18R1, IL6 | 4.59 | 8.08 |
| GO:0048634 | regulation of muscle organ development | 2.68E-03 | BDNF, FGFR2, FOXP1, GATA6, IL6 | 4.81 | 8.47 |
| GO:0048659 | smooth muscle cell proliferation | 1.91E-03 | EDNRA, FGFR2, FOXP1, IL6, PDE4D | 5.43 | 9.58 |
| GO:0050839 | cell adhesion molecule binding | 7.84E-05 | ADAMTS5, FN1, ITGA6, NRXN1, POSTN, PPAP2B, PTPN2, PTPRM, TRPC4 | 4.84 | 8.53 |
| GO:0051965 | positive regulation of synapse assembly | 2.16E-03 | BDNF, CBLN1, NRXN1 | 11.54 | 20.33 |
| GO:0055025 | positive regulation of cardiac muscle tissue development | 2.77E-03 | FGFR2, FOXP1, GATA6 | 10.34 | 18.23 |
| GO:0060038 | cardiac muscle cell proliferation | 9.07E-04 | FGFR2, FOXP1, GATA6, TGFB2 | 9.52 | 16.78 |
| GO:0060337 | type I interferon signaling pathway | 5.32E-03 | HLA-A, HLA-G, PTPN2, USP18 | 4.94 | 8.70 |
| GO:0071354 | cellular response to interleukin-6 | 2.09E-03 | IL6, PHB, PTPN2 | 12.00 | 21.15 |
| GO:0071556 | integral component of lumenal side of endoplasmic reticulum membrane | 2.77E-03 | HLA-A, HLA-DPA1, HLA-G | 10.34 | 18.23 |
| GO:1901019 | regulation of calcium ion transmembrane transporter activity | 1.42E-02 | FKBP1A, HAP1, PDE4D | 4.69 | 8.26 |
| GO:1902106 | negative regulation of leukocyte differentiation | 5.32E-03 | HLA-G, PTPN2, RUNX1, THOC5 | 4.94 | 8.70 |
| KEGG:00010 | Glycolysis / Gluconeogenesis | 6.91E-06 | ADH1A, ADH1B, ADH1C, ADH4, ADH6, ADH7, ALDH2 | 10.45 | 18.41 |
| KEGG:00071 | Fatty acid degradation | 8.27E-07 | ADH1A, ADH1B, ADH1C, ADH4, ADH6, ADH7, ALDH2 | 15.91 | 28.04 |
| KEGG:00350 | Tyrosine metabolism | 2.92E-06 | ADH1A, ADH1B, ADH1C, ADH4, ADH6, ADH7 | 17.14 | 30.21 |
| KEGG:00561 | Glycerolipid metabolism | 1.17E-02 | ALDH2, DGKH, PPAP2B | 5.08 | 8.96 |
| KEGG:00830 | Retinol metabolism | 6.54E-06 | ADH1A, ADH1B, ADH1C, ADH4, ADH6, ADH7, UGT2B7 | 10.77 | 18.98 |
| KEGG:00980 | Metabolism of xenobiotics by cytochrome P450 | 9.68E-06 | ADH1A, ADH1B, ADH1C, ADH4, ADH6, ADH7, UGT2B7 | 9.59 | 16.90 |
| KEGG:00982 | Drug metabolism | 7.40E-06 | ADH1A, ADH1B, ADH1C, ADH4, ADH6, ADH7, UGT2B7 | 10.14 | 17.88 |
| KEGG:04514 | Cell adhesion molecules (CAMs) | 8.57E-05 | ALCAM, HLA-A, HLA-DPA1, HLA-G, ITGA6, NRXN1, PTPRM, VCAN | 5.63 | 9.93 |
| KEGG:04940 | Type I diabetes mellitus | 5.97E-03 | HLA-A, HLA-DPA1, HLA-G | 6.98 | 12.30 |
| KEGG:05030 | Cocaine addiction | 7.63E-03 | BDNF, GNAI2, GRM3 | 6.12 | 10.79 |
| KEGG:05204 | Chemical carcinogenesis | 3.40E-06 | ADH1A, ADH1B, ADH1C, ADH4, ADH6, ADH7, SULT1A1, UGT2B7 | 9.76 | 17.19 |
| KEGG:05320 | Autoimmune thyroid disease | 8.87E-03 | HLA-A, HLA-DPA1, HLA-G | 5.66 | 9.98 |
| KEGG:05321 | Inflammatory bowel disease (IBD) | 2.96E-03 | HLA-DPA1, IL18R1, IL6, TGFB2 | 6.15 | 10.85 |
| KEGG:05330 | Allograft rejection | 4.82E-03 | HLA-A, HLA-DPA1, HLA-G | 7.89 | 13.91 |
| KEGG:05332 | Graft-versus-host disease | 8.75E-04 | HLA-A, HLA-DPA1, HLA-G, IL6 | 9.76 | 17.19 |
| KEGG:05410 | Hypertrophic cardiomyopathy (HCM) | 5.64E-03 | CACNG6, IL6, ITGA6, TGFB2 | 4.82 | 8.49 |
| KEGG:05416 | Viral myocarditis | 1.17E-02 | HLA-A, HLA-DPA1, HLA-G | 5.08 | 8.96 |
*
P-value was adjusted by Benjamini-Hochberg methods.